Communicators

are winners!

More News

28.10.2024
Recce Pharmaceuticals Receives Interim Efficacy Data and Safety Approval to Continue Phase II ABSSSI Clinical Trial
09.10.2024
Phase II Clinical Trial for Acute Bacterial Skin and Skin Structure Infections Recruitment Passes Halfway
05.08.2024
Successful Completion of Share Purchase Plan
15.07.2024
U.S. Department of Defense Grants US$2 million for RECCE® 327 Gel
08.07.2024
Positive Efficacy Data from Murdoch Children’s Research Institute in Study against WHO Priority Pathogen Acinetobacter baumannii
28.06.2024
Recce Pharmaceuticals Reports Positive Data From Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial of RECCE® 327
24.06.2024
Recce Pharmaceuticals Receives Ethics Approval to Centralise and Broaden RECCE® 327 Gel Clinical Trials across all Topical Bacterial Skin Infections
19.06.2024
Further R&D Rebate Approved
18.06.2024
RECCE® 327 added to The World Health Organization’s List of Antibacterial Products in Clinical Development
11.06.2024
Cohort Dosing Complete – Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial